By releasing proangiogenic factors, including vascular epidermal growth factor (VEGF) and prokineticin-2 (also known as Bv8), MDSCs support tumour angiogenesis and vasculogenesis [33,34] and promote both stemness and the proliferation of cancer cells [35,36]. Here, PROK2 is linked to neoplasm.